Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Multicenter Trial on Silibinin To Prevent Intracranial Recurrence After Gross-Total Resection of Single Brain Metastasis From Non-Small Cell Lung Cancer or Breast Cancer

NCT05689619 is registered in ClinicalTrials.gov with A.O.U. Città della Salute e della Scienza as lead sponsor.

NCT NCT05689619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Multicenter Trial on Silibinin To Prevent Intracranial Recurrence After Gross-Total Resection of Single Brain Metastasis From Non-Small Cell Lung Cancer or Breast Cancer
Lead sponsor
A.O.U. Città della Salute e della Scienza
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2023
Completion date
September 1, 2027
Enrollment
70 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, breast cancer, non small cell lung cancer